CEChidubem Ezenna

Chidubem Ezenna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chidubem Ezenna has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Meghna Joseph

    Department of Medicine, Medical College Thiruvananthapuram, Kerala, India

    10 shared publications
  • Mrinal Murali Krishna

    Department of Medicine, Medical College Thiruvananthapuram, Kerala, India

    10 shared publications
  • Andrew M. Goldsweig

    Department of Cardiovascular Medicine, Baystate Medical Center and Division of Cardiovascular Medicine, University of Massachusetts-Baystate, Springfield, MA, USA

    6 shared publications
  • Vinicius Pereira

    Faculty of Medicine, Universidad Austral, Pilar, Argentina

    5 shared publications
  • Ancy Jenil Franco

    Department of Medicine, Sri Muthukumaran Medical College Hospital and Research Institute, Chennai, Tamil Nadu, India

    4 shared publications
  • Andrew Michael Goldsweig

    Department of Cardiovascular Medicine, Baystate Medical Center, Springfield, MA 01199, USA

    4 shared publications

Latest Publications

  • Open Access

    Clinical Outcomes Following Transcatheter Aortic Valve Replacement With Hypertrophic Cardiomyopathy

    by Sammudeen Ibrahim, Hussein A. Noureldine, Malik Bary, Mahmoud H. Abdelnabi, Ramzi Ibrahim, Chidubem Ezenna, Hicham El Masry, Reza Arsanjani, Said Alsidawi

  • Long‐Term Outcomes of LAAO Versus DOACs in Nonvalvular Atrial Fibrillation: A Meta‐Analysis of Randomized Trials

    by Chidubem Ezenna, Khalid Sawalha, Sammudeen Ibrahim, Mrinal Murali Krishna, Meghna Joseph, Lakshmi Sai Niharika Janga, Samia Nadeem, Abdul‐Daaim Mohammed‐Murtala, Raiza Rossi, Andrew M. Goldsweig

    Background: Percutaneous left atrial appendage occlusion (LAAO) is an alternative strategy for stroke prevention in patients with nonvalvular atrial fibrillation (AF) with contraindications to long‐term oral anticoagulation therapy. However, evidence comparing the long‐term outcomes of LAAO with those of direct oral anticoagulants (DOAC) remains limited. Methods: A systematic search was conducted across PubMed, Scopus, and the Cochrane databases through April 2026. Co‐primary outcomes were major adverse cardiovascular and cerebrovascular events (MACCE; composite of cardiac death, stroke, or systemic embolism) and net adverse clinical events (NACE; composite of MACCE and non‐procedure‐related bleeding). Secondary endpoints included individual components of co‐primary endpoints, ischemic and hemorrhagic stroke, all‐cause death, major or clinically significant bleeding (procedure + non‐procedure related), and stroke or systemic embolism. The random‐effects model was used to generate risk ratios (RRs) and 95% CIs. Results: Four randomized controlled trials comprising 5890 AF patients and a median follow‐up of 3 years were included. There was no significant difference between LAAO and DOAC therapy in the risk of MACCE (RR 1.17; 95%CI 0.96–1.41; I 2 = 0%) or NACE (RR 0.89; 95%CI 0.65–1.24; I 2 = 85%). Both LAAO and DOAC therapy were similar in risk of cardiac death, stroke, systemic embolism, hemorrhagic stroke, ischemic stroke, all‐cause mortality, stroke or systemic embolism, and pericardial effusion. LAAO was associated with a lower risk of non‐procedure‐related bleeding (RR 0.60; 95%CI 0.47–0.76; I 2 = 59%). Conclusion: LAAO demonstrated efficacy comparable to DOAC therapy in reducing the risk of MACCE, NACE, and ischemic events, while significantly reducing the risk of non‐procedure‐related bleeding. Our findings support a tailored approach to stroke prevention in AF, wherein LAAO serves as an effective alternative for patients with contraindications to DOAC therapy.

  • Clinical manifestations, diagnosis, and therapeutic advances in May-Thurner Syndrome: A comprehensive literature review

    by Francis Ezekwueme, Chidubem Ezenna, Andrew Ndakotsu, Abdulraheem Eniola Hassan, George Akyea Blankson, Charles Agwuegbo, Chukwudumaga Iloh, Ekeneilichukwu Nnadi, Tamunoinemi Bob Manueli

  • Open Access

    Impact of July resident turnover on inpatient outcomes in patients with congestive heart failure and concomitant sepsis: Analysis of the national inpatient sample

    by Oghenetejiri Gbegbaje, Gabriel Alugba, Haris Muhammad, Favour Nelson, Chidubem Ezenna, Aparna Iyer, Vicky Kumar, Dipal R. Patel, Sidni Fullerton

    The notion of a “July effect,” suggesting that the influx of new residents in teaching hospitals every July (JU) may adversely affect patient care and outcomes, remains debatable. This study evaluated the impact of resident turnover in JU on patients admitted for congestive heart failure (CHF) and concomitant sepsis. This retrospective cohort study utilized data from the 2016 to 2020 National Inpatient Sample. Patients with CHF and concomitant sepsis hospitalized at teaching hospitals, as determined by International Classification of Diseases, 10th Revision (ICD-10) codes, were included. Univariate and multivariate logistic regression analyses were performed to estimate in-hospital mortality and secondary outcomes after adjustment for confounders, including cardiac arrest (CA), cardiogenic shock, non-ST segment elevation myocardial infarction, respiratory failure (RF), use of cardiac and respiratory devices, and healthcare resource utilization metrics such as length of stay (LOS) and total hospitalization charges (TOTCHG). Patients were classified according to the month of admission as JU or other months (OM) to investigate the potential impact of the “July effect” on patient outcomes. The study included 281,874 patients, of which 8% were in the JU group and 92% in the OM group. The mean age was 71 ± 13 years, with a slight male predominance (52% vs 48%), and most patients were White (70%). A total of 34,974 in-hospital deaths occurred, with no significant difference between the JU and OM groups (odds ratio [OR] = 0.95; 95% confidence interval [CI] = 0.85–1.06; p=0.329). Similarly, no significant differences were observed in CA (OR = 0.88; 95% CI = 0.70–1.11; p=0.282), RF (OR = 0.98; 95% CI = 0.90–1.06; p=0.597), ventilator use (OR = 0.99; 95% CI = 0.77–1.25; p=0.879), LOS (11.3 vs. 11.3), and TOTCHG (USD 136,377 vs. USD 136,181). However, lower rates of acute kidney injury were observed in the JU group compared with the OM group (OR 0.90; 95% CI, 0.84–0.98, p=0.011). This study demonstrates that the “July effect” does not significantly influence in-hospital outcomes in patients with CHF and concomitant sepsis. While mortality and major clinical outcomes were comparable across groups, lower rates of acute kidney injury were observed in patients admitted in JU. Further research is needed to understand the complex interplay between healthcare resident turnover and patient outcomes.

  • D-Mannose for prevention of recurrent urinary tract infection in adult women: An updated systematic review and meta-analysis of randomized controlled trials

    by Mrinal Murali Krishna, Meghna Joseph, Vinicius Pereira, Afshan Nizami, Chidubem Ezenna, Lal Sadasivan Sreemathy

    Purpose: Approximately 50%–60% of adult women experience at least one episode of urinary tract infection (UTI) during their lifetime, with 20%–24% of them experiencing recurrence within a year. Several randomized controlled trials have explored the efficacy and safety of D-mannose for the prevention of UTI in adult women but reported conflicting results. Objective: We performed a meta-analysis comparing D-mannose with placebo or no treatment for the prevention of UTI in adult women. Methods: We systematically searched PubMed, Scopus, and Cochrane Central databases for studies comparing D-mannose with placebo or no treatment for the prevention of UTI in adult women. The outcomes of interest were recurrent UTIs during follow-up and adverse events. Heterogeneity was assessed using I 2 statistics. Analysis followed the PRISMA guideline and was registered in the PROSPERO database. Results: The systematic review identified 4 randomized controlled trials (RCTs) including 890 participants (D-mannose n = 447, 50.22%). Recurrent UTI (RR 0.44; 95% CI 0.18–1.11; p = .082; I 2 = 90%) and adverse events (RR 2.19; 95% CI 0.68–7.05; p = .190; I 2 = 79%) did not differ significantly between the groups at the end of follow-up. Conclusion: Prophylaxis with D-mannose did not cause any difference in the risk of recurrent UTI during follow-up and adverse events in adult women. Fewer number of studies and heterogeneity in the results make it difficult to draw conclusions about the efficacy of D-mannose in preventing recurrent UTI. More placebo-controlled RCTs are required to confirm the efficacy and safety.


  • Intravascular imaging vs. angiography alone to guide percutaneous coronary intervention in older adults: a meta-analysis of randomized controlled trials

    by Chidubem Ezenna, Sammudeen Ibrahim, Mahmoud Ismayl, Mrinal Murali Krishna, Kuan-Yu Chi, Meghna Joseph, Zafer Akman, Raiza Rossi, Armin Nouri, Mohammad Al Mouslmani, et al.

    Background: Older adults undergoing percutaneous coronary intervention (PCI) face unique challenges due to complex anatomy and comorbidities. Intravascular imaging [including intravascular ultrasound (IVUS) and optical coherence tomography (OCT)] has been shown to improve PCI outcomes, but its benefits in older adults are less well established. We conducted a meta-analysis of randomized controlled trials (RCTs) to compare intravascular imaging with angiography alone to guide PCI in older adults. Methods: Cochrane, PubMed, and Scopus were searched for RCTs comparing intravascular imaging (IVUS or OCT) vs. angiography alone in adults aged ≥65 years. The outcome of interest was major adverse cardiovascular events (MACE) at the longest follow-up, as defined by each trial. Subgroup analyses were performed based on intravascular imaging modality, age group, and lesion complexity. Data were pooled using random-effects models, and heterogeneity was assessed using Higgins’ I ² statistic. Results: Nine RCTs ( n = 7164, intravascular imaging = 3703, angiography alone = 3461) met the inclusion criteria. Intravascular imaging significantly reduced MACE compared with angiography alone [relative risk (RR) 0.66, 95% confidence interval (CI) 0.56–0.77; P < 0.001; I ² = 0%]. IVUS demonstrated superiority over angiography alone (RR 0.55, 95% CI 0.43–0.72; P < 0.001; I ² = 0%), while OCT demonstrated only a trend toward MACE reduction (RR 0.80, 95% CI 0.62–1.02). Subgroup analyses indicated consistent benefits with intravascular imaging for adults aged ≥65 and ≥70 years, respectively, and among those with complex coronary lesions (RR 0.65, 95% CI 0.53–0.79; P < 0.001). Conclusion: Intravascular imaging guidance, especially IVUS, reduces MACE in older adults undergoing PCI compared with angiography alone.

  • Open Access

    Sex Differences in Cardiovascular Outcomes of Intravascular Imaging-Guided PCI

    by Chidubem Ezenna, Sammudeen Ibrahim, Prasana Ramesh, Mahmoud Ismayl, Mrinal Murali Krishna, Meghna Joseph, Kuan-Yu Chi, S. Elissa Altin, Michael G. Nanna, Andrew M. Goldsweig


  • Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis

    by Meghna Joseph, Mrinal Murali Krishna, Vanessa Karlinksi Vizentin, Henrique Provinciatto, Chidubem Ezenna

    Introduction: Azithromycin, with its antimicrobial and anti-inflammatory properties, has been explored as a potential option for preventing bronchopulmonary dysplasia (BPD) in preterm infants. Objective: We performed a meta-analysis of randomized controlled trials (RCTs) comparing azithromycin with placebo for the prevention of BPD in preterm infants. Methods: PubMed, Scopus, ClinicalTrials.gov, and Cochrane Central databases were searched for studies comparing azithromycin versus placebo in preterm infants. Outcomes of interest included the composite of BPD and death, BPD, death, grade 2 or higher necrotizing enterocolitis (NEC), grade 3 or 4 intraventricular hemorrhage (IVH), retinopathy of prematurity (RoP), duration of mechanical ventilation, and postnatal corticosteroid requirement. Random-effects model was used to generate risk ratio (RR), mean difference (MD), and 95% confidence interval (CI) (CRD42024558752). Results: The meta-analysis included 6 RCTs including 1,360 infants (azithromycin n = 680, 50%). The composite of BPD or death (RR: 0.95; 95% CI: 0.83–1.10; p = 0.53; I2 = 50.2%), BPD (RR: 0.98; 95% CI: 0.83–1.15; p = 0.77; I2 = 38.1%), death (RR: 0.88; 95% CI: 0.66–1.19; p = 0.41; I2 = 0%), NEC (RR: 0.94; 95% CI: 0.69–1.26; p = 0.67; I2 = 0%), IVH (RR: 1.22; 95% CI: 0.89–1.68; p = 0.22; I2 = 3.5%), RoP (RR: 1.35; 95% CI: 0.43–4.28; p = 0.61; I2 = 76.3%), duration of mechanical ventilation (MD: 0.13; 95% CI: −1.35 to 1.60; p = 0.87; I2 = 0%), and postnatal corticosteroid requirement (RR: 0.84; 95% CI: 0.64–1.08; p = 0.18; I2 = 34.5%) were similar between the groups. Conclusion: In preterm infants, azithromycin did not significantly change the risk of adverse clinical outcomes compared with placebo.

  • Efficacy of paclitaxel-coated versus uncoated balloon angioplasty for revascularization of coronary in-stent restenosis: a meta-analysis and metaregression

    by Mrinal Murali Krishna, Meghna Joseph, Chidubem Ezenna, Vinicius Pereira, Ancy Jenil Franco, Mahmoud Ismayl, Jennifer Rymer, Andrew M. Goldsweig

    Background: Treatment of in-stent restenosis (ISR) accounts for 10% of percutaneous coronary interventions in the USA. Paclitaxel-coated balloons (PCBs) are an alternative to uncoated balloons (UCBs) for ISR. Methods: We systematically searched PubMed, Scopus, and Cochrane Central for studies comparing PCB with UCB in treating ISR. Outcomes included late lumen loss, binary restenosis, target lesion revascularization (TLR), and major adverse cardiovascular events (MACE). Results: Eight trials including 1410 patients [PCB in 865 (61%), follow-up 6 months to 10 years) were identified. Angiographic outcomes of late lumen loss [mean difference: −0.50 mm; 95% confidence interval (CI): −0.66 to −0.33; P < 0.01] and binary restenosis [relative risk (RR): 0.22; 95% CI: 0.13–0.40; P < 0.01] at 6–8 months were lower with PCB. TLR at 6 months (RR: 0.16; 95% CI: 0.06–0.40; P < 0.001) and 1 year (RR: 0.45; 95% CI: 0.31–0.66; P < 0.001), MACE at 6 months (RR: 0.25; 95% CI: 0.16–0.38; P < 0.001), MACE at 3–5 years (RR: 0.54; 95% CI: 0.37–0.80; P = 0.002), and TLR at 3–5 years (RR: 0.51; 95% CI: 0.29–0.90; P = 0.021) were lower with PCB. Meta-regression revealed that ISR lesions in the left anterior descending artery were associated with lower rates of binary restenosis while the opposite was observed for left circumflex lesions. Conclusion: Revascularization of coronary ISR with PCB is associated with reduced late lumen loss, binary restenosis, TLR, CCE, and MACE. PCB may be a preferred strategy for coronary ISR.